Generic Dalvance Availability
Last updated on Apr 10, 2025.
Dalvance is a brand name of dalbavancin, approved by the FDA in the following formulation(s):
DALVANCE (dalbavancin hydrochloride - powder;intravenous)
-
Manufacturer: ABBVIE
Approval date: May 23, 2014
Strength(s): EQ 500MG BASE/VIAL [RLD]
Is there a generic version of Dalvance available?
No. There is currently no therapeutically equivalent version of Dalvance available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dalvance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods of administering dalbavancin for treatment of bacterial infections
Patent 6,900,175
Issued: May 31, 2005
Inventor(s): Cavaleri; Marco et al.
Assignee(s): Vicuron Pharmaceuticals Inc. (King of Prussia, PA)The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.
Patent expiration dates:
- May 23, 2028✓
- May 23, 2028
More about Dalvance (dalbavancin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: glycopeptide antibiotics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.